CuraCell Publishes Third and Final Clinical Report from CytoPLY™ Named-Patient Program, Demonstrating Tumour Responses Across Multiple Difficult-to-Treat Solid Tumours
Stockholm, Sweden - CuraCell TX AB (CuraCell) today announced the publication in Cytotherapy of the third and final scientific report emerging from its CytoPLY™ named-patient treatment program. The latest publication, “Targeting Intratumoral Heterogeneity in Pancreatic Cancer with Sequential TIL Infusions” adds pancreatic ductal adenocarcinoma (PDAC) to a growing body of clinical evidence supporting the potential of personalized tumour-infiltrating lymphocyte (TIL) therapy in heavily pretreated solid tumours.
Together, the three publications summarize clinical observations from named-
